Meredith has been with NeuroEndocrine Cancer Australia since February 2018, first serving as Project Officer / CRA & Nurse Educator before becoming CEO in September 2022. She has been instrumental in the development of the PLANET Registry and Patient App, the Neuroendocrine Cancer Optimal Care Pathway, fully accredited GP and Nurse Education Modules, the Living with Neuroendocrine Cancer Program and advocating for the approval for Belzutifan for VHL patients. Meredith plays an active role in patient support groups and has coordinated numerous Patient Education Forums across the country.
With over 40 years of oncology experience in metropolitan, rural, international, public, and private settings, Meredith brings a deep understanding of cancer care. She has led the commissioning of four private cancer care facilities in New South Wales and has broad expertise in accreditation, governance, quality systems, fundraising, and partnerships with pharmaceutical and philanthropic sectors. She is passionate about building strong teams that deliver best practice care while fostering professional development for healthcare providers.
Meredith currently serves on the Board of the Cancer Nurses Society of Australia (CNSA) and the International Neuroendocrine Cancer Alliance (INCA), contributing to national and global efforts to improve outcomes for people living with neuroendocrine cancer. She remains deeply committed to delivering world-class care and support to Neuroendocrine Cancer patients across Australia.
